Clinical Oncology Department, Barretos Cancer Hospital, Barretos 14784-400, SP, Brazil.
Pathology Department, Barretos Cancer Hospital, Barretos 14784-400, SP, Brazil.
Int J Mol Sci. 2022 Oct 3;23(19):11720. doi: 10.3390/ijms231911720.
The purpose of this study was to evaluate the status of Epstein-Barr virus (EBV) infection and the expression of programmed cell death ligand-1 (PD-L1) in tumor samples from patients with nasopharyngeal carcinoma (NPC).
Evaluation of EBV infection was performed through the detection of EBV-encoded small ribonucleic acids (EBER) by in situ hybridization, and PD-L1 expression was performed through immunohistochemistry.
In total, 124 samples were evaluated for EBER and 120 for PD-L1 expression. A total of 86.3% of cases were positive for EBER and 55.8% were positive for PD-L1. There was a correlation between EBER positivity and the presence of undifferentiated carcinoma histology ( = 0.007) as well as the absence of tobacco history ( = 0.019). There was a correlation between PD-L1 expression and EBER positivity ( = 0.004). There was no statistically significant difference between overall survival (OS) and EBER ( = 0.290) or PD-L1 ( = 0.801) expression.
This study corresponds to one of the largest cohorts of NPC in a non-endemic region. Phase III studies with checkpoint inhibitors are ongoing and may provide more data about the role of PD-L1 expression in this disease.
本研究旨在评估鼻咽癌（NPC）患者肿瘤样本中 EBV 感染和程序性死亡配体 1（PD-L1）表达的状况。
通过原位杂交检测 EBV 编码的小 RNA（EBER）来评估 EBV 感染，通过免疫组织化学检测 PD-L1 表达。
共评估了 124 例 EBER 和 120 例 PD-L1 表达样本。EBER 阳性率为 86.3%，PD-L1 阳性率为 55.8%。EBER 阳性与未分化癌组织学存在（ = 0.007）以及无烟草史（ = 0.019）相关。PD-L1 表达与 EBER 阳性相关（ = 0.004）。EBER（ = 0.290）或 PD-L1（ = 0.801）表达与总生存期（OS）之间无统计学差异。
本研究是在非流行地区进行的最大 NPC 队列之一。正在进行针对检查点抑制剂的 III 期研究，可能会提供有关 PD-L1 表达在该疾病中的作用的更多数据。
Zotero 插件
